Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'
A Randomized, Open-label, Single-dose, Two-sequence, and Two-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of AD-115A and the Administration of AD-1151 for Healthy Subjects in Fasting State
Addpharma Inc.
46 participants
Jan 27, 2026
INTERVENTIONAL
Conditions
Summary
The study compare and evaluate the safety and pharmacokinetic characteristics of a single dose administration of 'AD-115A' or 'AD-1151' in healthy adults.
Eligibility
Inclusion Criteria2
- The Age equal to or greater than 19 in healthy volunteers at the time of screening visit
- Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
Exclusion Criteria2
- Individuals who have taken drugs that induce (e.g., barbiturates) or inhibit drug-metabolizing enzymes within 30 days prior to the start of the study (first dosing day), or have taken drugs that may affect this study within 10 days prior to the start of the study (first dosing day)
- Other exclusions applied
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Single-dose oral administration of AD-115A or AD-1151 (200 mg tablet), according to randomized sequence.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07385235